tag rna-therapeutics 
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.
The Pharma Data
DECEMBER 3, 2020
Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. About Trimer-Tag © Technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. . EMERYVILLE, Calif.
The Pharma Data
MARCH 23, 2022
Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. But targeting Ebola virus polymerase has proven tough. A new route for interfering with Ebola virus infection.
Roots Analysis
JANUARY 28, 2024
Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.
Delveinsight
FEBRUARY 25, 2021
Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an all-stock agreement.
Drug Discovery World
NOVEMBER 13, 2023
Stefan Ewert, PhD, Associate Director, Biologics Center, Novartis Institutes for Biomedical Research, on: ‘Computational counterselection identifies nonspecific therapeutic biologic candidates’. The panel discussion will be hosted by chairperson Erasmus and Greiff on the current state of AI in antibody therapeutics.
Expert insights. Personalized for you.
52 
Let's personalize your content